These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34959722)

  • 1. Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office.
    Dri DA; Praticò G; Gaucci E; Marianecci C; Gramaglia D
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.
    Dri DA; Gaucci E; Torrieri I; Carafa M; Marianecci C; Gramaglia D
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials.
    Dri DA; Marianecci C; Carafa M; Gaucci E; Gramaglia D
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority.
    Vignot S; Dhanani A; Sainte-Marie I; de Ligniville Lajavardi L; Even G; Echemann M; Hulin N; Ménoret C; Maison P; Ratignier-Carbonneil C
    Front Pharmacol; 2022; 13():972660. PubMed ID: 36046816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When innovation outpaces regulations: The legal challenges for direct-to-patient supply of investigational medicinal products.
    Malone M; Ferguson P; Rogers A; Mackenzie IS; Rorie DA; MacDonald TM
    Br J Clin Pharmacol; 2022 Mar; 88(3):1115-1142. PubMed ID: 34390022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials.
    Doua YJ; Dominicus H; Mugwagwa J; Gombe SM; Nwokike J
    Trials; 2019 Apr; 20(1):212. PubMed ID: 30975193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
    Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
    Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From the Integrity of Potency Assays to Safe Clinical Intervention: Legal Perspectives.
    Roslin W; Mansnérus J
    Adv Exp Med Biol; 2023; 1420():151-163. PubMed ID: 37258789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trials on Advanced Therapy Investigational Medicinal Products in Spain (2004-2022): Experience and Challenges for the Future.
    Estévez Álamo J; Timón M; Sánchez Afán de Rivera I; Iriarte Torres B; Serrano Castro MA
    Adv Exp Med Biol; 2023; 1430():23-39. PubMed ID: 37526840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations.
    Lehmann B
    Child Adolesc Psychiatry Ment Health; 2008 Dec; 2(1):37. PubMed ID: 19063722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMEA and Gene Therapy Medicinal Products Development in the European Union.
    Papaluca Amati M; Pignatti F; Nolte A; Amerasinghe N; Gustafsson D; Moulon I; Le Courtois P
    J Biomed Biotechnol; 2003; 2003(1):3-8. PubMed ID: 12686717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.